MONTPELLIER, France, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces that it will present five posters at the Association for Research in Otolaryngology’s (ARO) 41st Annual MidWinter Meeting in San Diego, California, which takes place from February 9thto 14th, 2018.
The ARO MidWinter Meeting is a prestigious academic conference which brings together researchers and clinicians from around the world to present their work on diverse topics in the field of Otolaryngology. The five Sensorion studies selected by the Meeting’s reading committee to be presented at the Manchester Grand Hyatt in San Diego, California are:
Poster Presentation Titles:
- Twice versus once daily oral dosing of SENS-401 for 28 days reveals exposure duration driven treatment effect against severe acoustic trauma induced hearing loss in rats.
Session Title: Ototherapeutics II
Date of Presentation: Tuesday, 13 February
Presentation Time: 1:00 PM PST - Translational development of the clinical stage oral otoprotectant SENS-401 for sensorineural hearing loss.
Session Title: Ototherapeutics I
Date of Presentation: Monday, 12 February
Presentation Time: 1:00 PM PST - Tinnitus or Hearing Loss? Relationship between Gap-Pulse Inhibition of Acoustic Startle (GPIAS) deficits and ABR thresholds after repeated salicylate administration in rats.
Session Title: Tinnitus II
Date of Presentation: Sunday, 11 February
Presentation Time: 1:00 PM PST - Live Cell Imaging of neurite length and cell death in cultures of dissociated neurons from Scarpa’s ganglion.
Session Title: Inner Ear: Disease and Injury Models
Date of Presentation: Sunday, 11 February
Presentation Time: 1:00 PM PST - Live Cell Imaging of cisplatin induced ototoxicity in Organ of Corti explant cultures reveals differences in sensitivity and lesion kinetics between hair cells and supporting cells.
Session Title: Ototoxicity
Date of Presentation: Saturday, 10 February
Presentation Time: 1:00 PM PST
“Sensorion is pleased to present this important research,” stated Pierre Attali, MD, Chief Medical Officer, Sensorion. “Our clinical and research programs continue to advance and we look forward to multiple key catalysts in 2018 for our clinical candidates SENS-111 in vestibular disorders and SENS-401, which is expected to enter the phase 2 clinical program for hearing disorders in the first half of the year.”
About SENS-401
SENS-401, R-azasetron besylate, is a drug candidate that aims to protect and preserve inner ear tissue when lesions are present that can cause progressive or sequelar hearing impediments. A small molecule that can be taken orally or via an injection, SENS-401 has received Orphan Drug Designation in Europe for the treatment of sudden sensorineural hearing loss, and Orphan Drug Designation from the US FDA for the prevention of platinum-induced ototoxicity in pediatric population. It is one of the two enantiomer forms of azasetron, a racemic molecule belonging to the family of setrons marketed in Asia under the name Serotone. Enantiomers are molecules that have an identical chemical structure but a different configuration in space, i.e. they are mirror images of each other, like a person’s left and right hands. The pharmacological and pharmacokinetic tests completed to date have shown a superior drug candidate profile for SENS-401 compared with the other enantiomer or the racemic form.
About Sensorion
Sensorion is a biotech company pioneering novel treatments of inner ear diseases such as severe vertigo, tinnitus or hearing loss. Two products are currently in the clinical development stage: SENS-111, in phase 2 in acute unilateral vestibulopathy (vestibular neuritis), and SENS-401, which has completed a phase 1 trial. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop first-in-class easy-to-administer, notably orally active, drugs for treating and preventing hearing loss and the symptoms of bouts of vertigo and tinnitus.
Based in Montpellier, Southern France, Sensorion has received financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.
Sensorion has been listed on the Euronext Growth Paris exchange since April 2015.
www.sensorion-pharma.com
Contacts
| Sensorion | Investor Relations – International |
| Nawal Ouzren | LifeSci Advisors LLC |
| Directeur général | Chris Maggos – Directeur général, Europe |
| contact@sensorion-pharma.com | chris@lifesciadvisors.com |
| Tel.: 04 67 20 77 30 | Tel.: +41 79 367 6254 |
| Libellé : SENSORION | Press Relations |
| Code ISIN : FR0012596468 | Alize RP |
| Mnémonique : ALSEN | Caroline Carmagnol & Wendy Rigal |
| sensorion@alizerp.com | |
| Tel.: +33 1 44 54 36 66 |
Disclaimer
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the Document de référence registration document filed with the Autorité des marchés financiers (AMF- French Financial Market Authority) on September 6, 2017 under n°R.17-062 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
